No description available.

Adenocarcinoma pancreático é um tumor maligno com mau prognóstico, e por isso há necessidade de aperfeiçoamento ou criação de novas estratégias terapêuticas. A vacinação baseada em DCs é uma das abordagens mais promissoras, uma vez que as DCs são as células apresentadoras de antígenos (APCs) mais potentes e centrais para a indução e manutenção de uma resposta imune. Entretanto, em pacientes com câncer, a geração e a função de DCs podem ser deficientes, impondo um obstáculo para o sucesso de seu uso. Neste trabalho, nós descrevemos a geração in vitro de DCs a partir de células mononucleares do sangue periférico (PBMC) obtidas de pacientes ictéricos com câncer de pâncreas e, também, o efeito do plasma ictérico (PI) sobre as culturas de DCs de doadores saudáveis. PBMCs foram separadas do sangue obtido de 22 pacientes e 22 doadores saudáveis. Células aderentes foram cultivadas com GM-CSF e IL-4 (50ng/mL) por 7 dias. No 5o dia, TNF-<font face=\"symbol\">a (50ng/mL) foi adicionado para a maturação das DCs. Culturas foram realizadas em 10% PI ou plasma normal (PN). Células não aderentes foram coletadas no 7o dia, marcadas com anticorpos monoclonais anti-CD86, CD11c, CD14 e HLA-DR e analisados por citometria de fluxo. Células de pacientes, cultivadas em 10% de PI, quando comparadas com células de doadores saudáveis, cultivadas em 10% PN, apresentaram expressão reduzida (p<0,05) de CD86 e HLADR. É interessante observar que células geradas de PBMCs de pacientes não expressaram CD11c, diferente das células derivadas de doadores saudáveis. A presença de PI nas culturas dos doadores saudáveis causou uma significante diminuição na porcentagem de expressão de células HLA-DR+, CD11c+, CD86. Finalmente, quando PBMCs de pacientes foram cultivadas em PN, houve um aumento na expressão de HLA-DR e CD86 (p<0,05). Os ensaios de proliferação demonstraram também que as células de pacientes ictéricos tiveram capacidade aloestimuladora de linfócitos reduzida, quando comparada a de células de doadores saudáveis. Estes dados indicam uma alteração importante na capacidade das células de pacientes se diferenciarem em DCs in vitro, um fenômeno que parece depender tanto de fatores solúveis presentes no plasma e sobre as próprias células. / Pancreatic adenocarcinoma (PAdc) is an aggressive malignancy with poor prognosis, urging for improved or new therapeutic strategies. DC-based vaccination is one of such promising approaches. DC are the most potent antigen-presenting cells and central to the induction and maintenance of an immune response. However, in cancer patients DC generation and function may be deficient, imposing an obstacle to the success of their use. Here, we describe the in vitro generation of DC from peripheral blood mononuclear cells (PBMC) obtained from jaundiced patients with PAdc and, also, the effect of jaundiced plasma (JP) in the phenomenon. PBMC were separated from blood obtained from 10 patients and 10 healthy controls over a density gradient. Adherent cells were cultured with GM-CSF and IL-4 (50ng/mL) for 7 days. On the 5th day, TNF-<font face=\"symbol\">a (50ng/mL) was added for DC activation. Cultures were performed in 10% JP or normal plasma (NP). Non-adherent cells were harvested at day 7, labeled with FITC- or PE-conjugated monoclonal antibodies against CD86, CD11c, CD14, HLA-DR and analyzed by flow cytometry. Patients\' cells, cultured in 10% JP, compared to healthy donors\' cells, cultured in 10% NP, had a significantly (p<0.05) lower expression of CD86 and HLA-DR. It is noteworthy that cells generated from patients\' PBMC did not express CD11c, while from those derived from healthy donors\' cells did so. The presence of JP in healthy donors\' cells cultures caused a significant decrease in the percentage of HLA-DR+, CD11c+ and CD86+ cells. Finally, when patients\' PBMC were cultured in NP, a significant increase in HLA-DR and in CD86 expression occurred. MLR assays also demonstrated that cells from jaundice patients had decreased capacity to stimulate alloestimulation of lymphocytes when compared to healthy donors. These data indicate a significant alteration in the patients\' PBMC ability to differentiate into DC in vitro, a phenomenon that seems to depend both on soluble factors present in plasma and on the cells, themselves.

Adenocarcinoma pancreático é um tumor maligno com mau prognóstico, e por isso há necessidade de aperfeiçoamento ou criação de novas estratégias terapêuticas. A vacinação baseada em DCs é uma das abordagens mais promissoras, uma vez que as DCs são as células apresentadoras de antígenos (APCs) mais potentes e centrais para a indução e manutenção de uma resposta imune. Entretanto, em pacientes com câncer, a geração e a função de DCs podem ser deficientes, impondo um obstáculo para o sucesso de seu uso. Neste trabalho, nós descrevemos a geração in vitro de DCs a partir de células mononucleares do sangue periférico (PBMC) obtidas de pacientes ictéricos com câncer de pâncreas e, também, o efeito do plasma ictérico (PI) sobre as culturas de DCs de doadores saudáveis. PBMCs foram separadas do sangue obtido de 22 pacientes e 22 doadores saudáveis. Células aderentes foram cultivadas com GM-CSF e IL-4 (50ng/mL) por 7 dias. No 5o dia, TNF-<font face=\"symbol\">a (50ng/mL) foi adicionado para a maturação das DCs. Culturas foram realizadas em 10% PI ou plasma normal (PN). Células não aderentes foram coletadas no 7o dia, marcadas com anticorpos monoclonais anti-CD86, CD11c, CD14 e HLA-DR e analisados por citometria de fluxo. Células de pacientes, cultivadas em 10% de PI, quando comparadas com células de doadores saudáveis, cultivadas em 10% PN, apresentaram expressão reduzida (p<0,05) de CD86 e HLADR. É interessante observar que células geradas de PBMCs de pacientes não expressaram CD11c, diferente das células derivadas de doadores saudáveis. A presença de PI nas culturas dos doadores saudáveis causou uma significante diminuição na porcentagem de expressão de células HLA-DR+, CD11c+, CD86. Finalmente, quando PBMCs de pacientes foram cultivadas em PN, houve um aumento na expressão de HLA-DR e CD86 (p<0,05). Os ensaios de proliferação demonstraram também que as células de pacientes ictéricos tiveram capacidade aloestimuladora de linfócitos reduzida, quando comparada a de células de doadores saudáveis. Estes dados indicam uma alteração importante na capacidade das células de pacientes se diferenciarem em DCs in vitro, um fenômeno que parece depender tanto de fatores solúveis presentes no plasma e sobre as próprias células. / Pancreatic adenocarcinoma (PAdc) is an aggressive malignancy with poor prognosis, urging for improved or new therapeutic strategies. DC-based vaccination is one of such promising approaches. DC are the most potent antigen-presenting cells and central to the induction and maintenance of an immune response. However, in cancer patients DC generation and function may be deficient, imposing an obstacle to the success of their use. Here, we describe the in vitro generation of DC from peripheral blood mononuclear cells (PBMC) obtained from jaundiced patients with PAdc and, also, the effect of jaundiced plasma (JP) in the phenomenon. PBMC were separated from blood obtained from 10 patients and 10 healthy controls over a density gradient. Adherent cells were cultured with GM-CSF and IL-4 (50ng/mL) for 7 days. On the 5th day, TNF-<font face=\"symbol\">a (50ng/mL) was added for DC activation. Cultures were performed in 10% JP or normal plasma (NP). Non-adherent cells were harvested at day 7, labeled with FITC- or PE-conjugated monoclonal antibodies against CD86, CD11c, CD14, HLA-DR and analyzed by flow cytometry. Patients\' cells, cultured in 10% JP, compared to healthy donors\' cells, cultured in 10% NP, had a significantly (p<0.05) lower expression of CD86 and HLA-DR. It is noteworthy that cells generated from patients\' PBMC did not express CD11c, while from those derived from healthy donors\' cells did so. The presence of JP in healthy donors\' cells cultures caused a significant decrease in the percentage of HLA-DR+, CD11c+ and CD86+ cells. Finally, when patients\' PBMC were cultured in NP, a significant increase in HLA-DR and in CD86 expression occurred. MLR assays also demonstrated that cells from jaundice patients had decreased capacity to stimulate alloestimulation of lymphocytes when compared to healthy donors. These data indicate a significant alteration in the patients\' PBMC ability to differentiate into DC in vitro, a phenomenon that seems to depend both on soluble factors present in plasma and on the cells, themselves.

Pancreatic cancer is known to be one of the most life-threatening cancers characterized by aggressive local invasion and distant metastasis. The high basal level of autophagy in pancreatic cancer may be responsible for the low chemotherapeutic drug response rate and poor disease prognosis. However, the clinical application of autophagy inhibitors was unsatisfactory due to their toxicity and minimal single-agent anticancer efficacy. Hence, oncologists begin to consider the tumor microenvironment when exploring new drug targets. In the present study, the anti-tumorigenic mechanisms of two major phytochemicals derived from Chinese medicinal herbs had been investigated against pancreatic cancer development. Calycosin is a bioactive isoflavonoid of the medicinal plant Astragalus membranaceus. Our results have shown that calycosin inhibited the growth of various pancreatic cancer cells both in vitro and in vivo by inducing cell cycle arrest and apoptosis. Alternatively, calycosin also facilitated MIA PaCa-2 pancreatic cancer cell migration in vitro and increased the expression of epithelial-mesenchymal transition (EMT) biomarkers in vivo. Further mechanistic study suggests that induction of the Raf/MEK/ERK pathway and facilitated polarization of M2 tumor-associated macrophage in the tumor microenvironment both contribute to the pro-metastatic potential of calycosin in pancreatic cancer. These events appear to be associated with calycosin-evoked activation of TGF-β signaling, which may explain the paradoxical drug actions due to the dual roles of TGF-β as both tumor suppressor and tumor promoter in pancreatic cancer development under different conditions. Isoliquiritigenin (ISL) is a chalcone obtained from the medicinal plant Glycyrrhiza glabra, which can be a precursor for chemical conversion to form calycosin. Results have shown that ISL decreased the growth and EMT of pancreatic cancer cells in vitro, probably due to modulation of autophagy. ISL-induced inhibition of autophagy subsequently promoted reactive oxygen species (ROS) production, leading to induction of apoptosis in pancreatic cancer cells. Such phenomenon also contributed to the synergistic growth-inhibitory effect in combined treatment with the orthodox chemotherapeutic drug 5-fluorouracil. In addition, ISL-induced tumor growth inhibition in vivo was further demonstrated in a tumor xenograft mice model of pancreatic cancer. ISL promoted apoptosis and inhibited autophagy in the tumor tissues. Study on immune cells indicates that ISL could reduce the number of myeloid-derived suppressor cells (MDSCs) both in tumor tissue and in peripheral blood, while CD4+ and CD8+ T cells were increased correspondingly. In vitro test has revealed that ISL inhibited the polarization of M2 macrophage along with its inhibition of autophagy in M2 macrophage. These immunomodulating effects of ISL had reversed the pro-invasive role of M2 macrophage in pancreatic cancer.In conclusion, calycosin acts as a "double-edged sword" on the growth and metastasis of pancreatic cancer, which may be related to the dual roles of TGF-β and its influence on the tumor microenvironment. Alternatively, ISL consistently inhibited the growth and metastatic drive of pancreatic cancer through regulation of autophagy and reprogramming of the immune system. The differential modes of action of these compounds have provided new insights in the development of effective pancreatic cancer treatment adjuvants.

Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor prognosis. To improve the prognosis, novel molecular markers and targets for earlier diagnosis and adjuvant and/or neoadjuvant treatment are needed. Recent advances in human genome research and high-throughput molecular technologies make it possible to cope with the molecular complexity of malignant tumors. With DNA array technology, mRNA expression levels of thousand of genes can be measured simultaneously in a single assay. As several studies using microarrays in PDAC have already been published, this review attempts to compare the published data and therefore to validate the results. In addition, the applied techniques are discussed in the context of pancreatic malignancies. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

La distribution in vivo des médicaments est étudiée par des techniques quantitatives faiblement ou non résolues spatialement. Avec l'apparition des thérapies personnalisées, des études plus approfondies sont nécessaires pour connaître précisément le comportement des molécules vectorisées sous la forme de nanoparticules (NPs). Dans le cadre du programme européen Ternanomed, ce projet de recherche a pour objectif d’évaluer la capacité de deux techniques d’imagerie appliquées à l’étude de la distribution de nanomédicaments à base de squalène et de Cis platine (Cis-Pt). Ces deux techniques ont été sélectionnées pour leur apport d’informations complémentaires à l’échelle des organes et des tissus : i) l’imagerie par résonnance magnétique (IRM) pour suivre in vivo la biodistribution de NPs modèles à base de Cis-Pt et BiSqualène (BiSQ), marquées par des agents de contraste type oxyde de fer (USPIO), ii) l’imagerie de microfluorescence X, couplée au rayonnement synchrotron (SR-μXRF), qui ne nécessite pas de marquage préalable des nanomédicaments, pour le suivi tissulaire du Cis-Pt.Concernant l’approche par IRM, nous avons encapsulé avec succès nos USPIO synthétisées au sein des NPs de Cis-Pt BiSQ (210nm, polydispersité 0,1), tout en leur conférant un pouvoir contrastant à 7 tesla (r2=404 ms.mol-1 et r1=3 ms.mol-1). Ces NPs nouvellement préparées sont également traçables chez notre modèle murin Nudes. Les résultats de biodistribution montrent une arrivée rapide du contraste dans les organes épurateurs : le foie et la rate (5 minutes après l’injection). Au final, l’analyse par IRM a permis d’obtenir les données de biodistribution en temps réel des NPs à base de Cis Pt BiSQ, grâce au suivi du contraste apporté par les USPIO encapsulés. Concernant l’imagerie par SR-μXRF, nous avons démontré que cette technique est suffisamment sensible pour détecter et cartographier le Cis-Pt, vectorisé par nos NPs modèles. La distribution du Cis Pt a été quantifiée localement à partir d’une référence interne de concentration connue, le Zinc, à partir de notre méthode validée par le dosage globale du Platine par spectrométrie d’absorption atomique. Lorsque notre référence tissulaire n’est pas distribuée de façon homogène, une méthode semi-quantitative a été mise au point pour comparer la distribution à 2h, 8h et 24h, tel qu’au niveau des coupes de tumeurs PANC-1.Au final, ces travaux ont permis de démontrer, que la SR-μXRF et l’IRM sont des approches de choix pour l’étude pharmacocinétique et pharmacodynamique de nanomédicaments tels que les NPs à base de Cis-Pt. La technique de microfluorescence X contribue au caractère original et pionnier de ce travail de recherche, apportant des nouveaux résultats de détection et quantification important dans le domaine des nanomédecines. / Nowadays, the in vivo distribution of drugs is studied by non-spatial or partially spatial quantitative techniques. With the development of personalized therapies, many studies are required to know the in vivo behaviour of these innovative treatments, which target drugs, such as nanoparticles (NPs). Into the European funded program Ternanomed, the aim of this multidisciplinary research project was to evaluate two complementary imaging methods to study the distribution of squalene and Cis platinum (Cis Pt) NPs. The 2 imaging methods were selected to provide complementary data at the scale of organs and tissues: i) Magnetic resonance imaging (MRI) to monitor the in vivo biodistribution of NPs models based on Cis-Pt and BiSqualene (BiSQ), labelled with "UltraSmall Iron Oxide Particle" (USPIO) contrast agents, ii) X-ray microfluorescence imaging, coupled with synchrotron radiation (SR-μXRF) without any labelling of these nanomedicines, by following the Cis-Pt drug distribution into tissues.Regarding the MRI approach, we first successfully prepared Cis-Pt BiSQ NPs loading with USPIO (210nm, polydispersity 0,1). These NPs were given a contrast at 7 Tesla (r2 = 404 ms.mol-1 and r1 = 3 ms.mol-1). These newly prepared and characterized NPs were also trackable into our Nude murine model. The results show a rapid arrival of contrast in the liver and spleen scavengers (5 minutes after injection). Ultimately, MRI analysis yielded real-time biodistribution data for Cis-Pt BiSQ-based NPs by monitoring the contrast provided by encapsulated USPIO. Regarding the SR-μXRF imaging analysis, we demonstrated that this technique is very sensitive to detect and map the Cis-Pt distribution, the drug vectorized by our squalene NPs models. Additionally, a local quantitative analysis is feasible when a microelement present in the tissue is used as a reference, in our study the Zinc element. The distribution of Cis-Pt was quantified in the hepatic, renal and fat tissues, after 2h and 24h, with our method validated by the global Platinum microanalyse using atomic absorption spectrometry. When the tissue reference appears not homogenously distributed, a semi-quantitative analysis method is possible to compare the distribution such as into PANC-1 tumour sections.Finally, these two complementary approaches illustrate the use of SR-μXRF and lay the optimized bases of MRI to study the pharmacokinetics and pharmacodynamics of two new types of Cis-Pt/squalene NPs. The SR-μXRF technique, newly used in pharmaceutical field, had an effective contribution to these original and pioneering research studies with an original way of in vivo assessment of the distribution of drug embedded into nanomedicine system. The issue of detecting correct and measurable distribution of the drugs is extremely important, timely and relevant to improve current knowledge in the state of the art. This research study brings new data which can produce significant impact to the overall area of nanomedicine.